Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, today announced that BAFIERTAMâ„¢ (monomethyl fumarate), a novel fumarate for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, has commercially launched and is now available in the U.S.
HIGH POINT, N.C.--(BUSINESS WIRE)--Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, today announced that BAFIERTAM™ (monomethyl fumarate), a novel fumarate for adults for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, will be commercially available in the U.S. September 1, 2020. BAFIERTAM was approved by the U.S. Food and Drug Administration (FDA) on April 28, 2020.
HIGH POINT, N.C.--(BUSINESS WIRE)-- Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, today announced that BAFIERTAM™ (monomethyl fumarate), a novel fumarate for adults for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, will be commercially available in the U.S. September 1, 2020. BAFIERTAM was approved by the U.S. Food and Drug Administration (FDA) on April 28, 2020.
Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted final approval of BAFIERTAM™ (monomethyl fumarate) delayed-release capsules for the treatment of relapsing forms of multiple sclerosis (MS).
HIGH POINT, N.C.--(BUSINESS WIRE)--Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, announced today that the United States Court of Appeals for the Federal Circuit has upheld the United States District Court for the District of Delaware’s decision that Banner’s BAFIERTAM™ product does not infringe the extended portion (under the Hatch-Waxman Act) of U.S. Patent Number 7,619,001 (the “‘001 patent”) which protects Biogen’s product Tecfidera®.1
Tecfidera®(Dimethyl fumarate): Biogen International GmbH et al v. Banner Life Sciences LLC
Bionpharma, a New Jersey-based pharmaceutical startup founded last year by five former RanbaxyBSE 5.63 % executives and backed by strategic and financial investors, has acquired a portfolio of approximately 25 products from specialty drug maker Banner Life Sciences.
ES and IM are leading European chemical manufacturers in their respective market segments and have a 75-year tradition of translating the latest research results into scalable intermediates and end products. In the context of custom synthesis, ES develops and produces chemical intermediate products for agriculture and other industries. IM produces maleic anhydride, a large number of intermediates, derivatives and esters. With a longstanding and broad customer base, ES and IM generated combined sales of around €200 million for the 2014 financial year and have around 390 employees.